TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $6,475,280.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 56,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $115.63, for a total value of $6,475,280.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $8,566,679.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

TransMedics Group Trading Up 2.9 %

NASDAQ:TMDX opened at $127.99 on Monday. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $129.66. The firm has a 50-day moving average price of $85.54 and a two-hundred day moving average price of $77.32. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The company had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same period last year, the business posted ($0.08) earnings per share. TransMedics Group’s revenue was up 132.9% on a year-over-year basis. On average, equities analysts expect that TransMedics Group, Inc. will post 0.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. RiverPark Advisors LLC boosted its holdings in shares of TransMedics Group by 361.1% in the 1st quarter. RiverPark Advisors LLC now owns 6,082 shares of the company’s stock worth $450,000 after buying an additional 4,763 shares during the last quarter. Fidelis Capital Partners LLC bought a new stake in TransMedics Group in the first quarter worth about $35,000. BNP Paribas Financial Markets raised its position in TransMedics Group by 35.1% in the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company’s stock worth $1,286,000 after acquiring an additional 4,518 shares during the period. Oak Ridge Investments LLC boosted its stake in TransMedics Group by 59.5% in the first quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company’s stock valued at $1,351,000 after acquiring an additional 6,813 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of TransMedics Group by 3.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock valued at $53,977,000 after acquiring an additional 21,737 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on TMDX shares. TD Cowen boosted their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Piper Sandler reissued an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research report on Wednesday, May 1st. JPMorgan Chase & Co. raised their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Canaccord Genuity Group boosted their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Finally, Oppenheimer raised their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.